Company news
Microba Life Sciences Limited (ASX:MAP) news
Microba Life Sciences Limited news releases on 6ix. Latest, Sep 24, 2026: Appointment of Interim Chief Executive Officer
Press releases & updates
Appointment of Interim Chief Executive Officer
September 24, 2026
GSS and MAP agree to Commercial Terms for Merger
September 21, 2026
2026 Annual Report & Appendix 4E
August 30, 2026
Genetic Signatures and Microba in Merger Discussions
August 25, 2026
Q4 FY26 Quarterly Investor Presentation & Webinar
July 15, 2026
Investor presentation - path to cashflow breakeven
June 11, 2026
Pause in Trading
June 2, 2026
Q3 FY26 Quarterly Investor Presentation & Webinar
April 29, 2026
Appendix 4D & FY26 Interim Report
February 25, 2026
Q2 FY26 Quarterly Investor Presentation & Webinar
January 28, 2026
Q2 FY26 Quarterly Activities Report & Appendix 4C
January 28, 2026
Microba receives $3 million R&D Tax Incentive Refund
December 2, 2025
Q1 FY26 Quarterly Investor Presentation & Webinar
October 27, 2025
Q1 FY26 Quarterly Activities Report & Appendix 4C
October 27, 2025
2025 Annual Report & Appendix 4E
August 26, 2025
Q4 FY25 Quarterly Investor Presentation & Webinar
July 21, 2025
Q4 FY25 Quarterly Activities Report & Appendix 4C
July 21, 2025
Disclosure Document - Prospectus
June 27, 2025
Strategic Investment & Equity Raise Presentation
June 23, 2025
Reinstatement to Quotation
June 23, 2025
Microba secures $14.5 million to drive clinical adoption
June 23, 2025
Suspension from Quotation
June 23, 2025
Trading Halt
June 18, 2025
MetaPanel Pathogen Study Delivers Breakthrough Results
May 20, 2025
Microba Announces Landmark GI Study Results From Over 4,600 Patients
May 14, 2025
Landmark GI Study Results from over 4,600 patients
May 13, 2025
Q3 FY25 Quarterly Investor Presentation & Webinar
April 29, 2025
Q3 FY25 Quarterly Activities Report & Appendix 4C
April 29, 2025
Microba Delivers Landmark IBD Results & Signs Major Gastro Partner
April 29, 2025
Appendix 4D & FY25 Interim Report
February 25, 2025
Q2 FY25 Quarterly Investor Presentation & Webinar
January 28, 2025
Q2 FY25 Quarterly Activities Report & Appendix 4C
January 28, 2025
Trading Update
November 28, 2024
Microba receives $6 million R&D Tax Incentive Refund
November 17, 2024
Q1 FY25 Quarterly Investor Presentation
October 28, 2024
Q1 FY25 Quarterly Activities Report & Appendix 4C
October 28, 2024
2024 Annual Report & Appendix 4E
August 28, 2024
Q4 FY24 Quarterly Investor Presentation & Webinar
July 24, 2024
Q4 FY24 Quarterly Activities Report & Appendix 4C
July 24, 2024
Completion of Autoimmune Program with Ginkgo Bioworks
June 27, 2024
Q3 FY24 Quarterly Investor Presentation
April 22, 2024
Q3 FY24 Quarterly Activities Report & Appendix 4C
April 22, 2024
Microba receives $6.08 million R&D Tax Incentive Refund
April 10, 2024
MetaPanel Launch Investor Presentation
March 12, 2024
MetaPanel Diagnostic Test Launched with Sonic Healthcare
March 12, 2024
Appendix 4D & FY24 Interim Report
February 27, 2024
Q2 FY24 Quarterly Investor Presentation
January 29, 2024
Q2 FY24 Quarterly Activities Report & Appendix 4C
January 29, 2024
Successful IBD Phase I Clinical Trial
December 6, 2023
Research Agreement Executed with IFF for Allergy Program
December 3, 2023